Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468130 · ClinicalTrials.gov registry record · NA
Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children
A NA study, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT00468130 is a NA study that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 13 participants.
The verdict
NCT00468130, a NA study, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale. (2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity. The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.
Interventions
- DRUG Placebos
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468130
The ClinicalTrials.gov registry entry for NCT00468130 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT00468130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00468130 about?
NCT00468130 is a clinical study titled "Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children". Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale. (2) Aripiprazole treatment will be superior to placebo in the acute treatment of global...
What is the current status of trial NCT00468130?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2006-05. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00468130?
The interventions under investigation include: Placebos (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00468130?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.